Pulmonary Fibrosis News and Research

RSS

UVA research could help identify COVID-19 survivors at risk for long-haul lung problems

UVA Health researchers have discovered a potential way to predict which patients with severe COVID-19 are likely to recover well and which are likely to suffer "long-haul" lung problems.

15 Mar 2024

Immune cells in overdrive: Study finds unbalanced response worsens lung infections

CD4+ T cells have been highlighted in the scientific literature for the important role they play in the immune response to lung infections.

8 Feb 2024

UVA scientists develop new approach to machine learning for identifying heart drug

University of Virginia scientists have developed a new approach to machine learning – a form of artificial intelligence – to identify drugs that help minimize harmful scarring after a heart attack or other injuries.

5 Feb 2024

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to form Calluna Pharma Inc. (Calluna).

From Calluna Pharma 24 Jan 2024

Morphine shows potential as effective cough therapy for pulmonary fibrosis, study finds

The efficacy of the controlled release of low-dose morphine as treatment against that of a placebo in idiopathic pulmonary fibrosis.

18 Jan 2024

COMPANION study of digital therapy demonstrates reduced anxiety in patients with pulmonary fibrosis

Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced positive results of the COMPANION study (NCT05330312), investigating the efficacy of AlmeeTM, a 9-week digital cognitive behavioral therapy (CBT) accessed through a smartphone or tablet.

8 Jan 2024

Digital CBT intervention reduces anxiety and improves quality of life for pulmonary fibrosis patients

Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital cognitive behavioral therapy (CBT) intervention accessed through a smartphone or tablet.

8 Jan 2024

Uncovering the true culprit behind nanofiber-induced lung disease

The pathogenic potential of inhaling the inert fibrous nanomaterials used in thermal insulation (such as asbestos or fiberglass) is actually connected not to their chemical composition, but instead to their geometrical characteristics and size.

5 Jan 2024

Healthy fats from fish and nuts may slow lung scarring, delay transplants

Could healthy fats found in nuts and fish slow the progression of potentially deadly lung scarring known as pulmonary fibrosis and delay the need for lung transplants?

2 Jan 2024

Study suggests iron accumulation plays a central role in senescence and fibrosis

Researchers investigated the association between cellular damage, iron buildup, senescence, and fibrosis.

18 Dec 2023

Study establishes iron accumulation as a driver of pathological senescence and fibrosis

Fibrosis is associated with various chronic and life-threatening conditions, including pulmonary fibrosis, liver cirrhosis, kidney disease, and cardiovascular diseases, among others.

14 Dec 2023

Insilico Medicine hosts three webinars to unveil latest technology breakthroughs

Insilico Medicine ("Insilico"), an artificial intelligence (AI)-driven, clinical stage biotechnology company and leader in AI drug discovery platform technology, is hosting three webinars unveiling its latest technology breakthroughs Nov. 28-30, 2023.

29 Nov 2023

Pitt researcher receives $1.95 million grant to study cell communication

Day by day, we communicate with our office colleagues to accomplish tasks that are necessary to function.

21 Nov 2023

Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine ("Insilico") has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.

16 Oct 2023

Long-term lung issues and lower quality of life plague COVID-19 survivors, new study warns

New research in Scientific Reports reveals that COVID-19 survivors, especially those who had severe or critical illness, face long-term lung complications and a reduced quality of life. The study recommends 6-monthly pulmonary function tests for these survivors to monitor for chronic lung damage.

15 Oct 2023

New analytical tool could lead to a cure for idiopathic pulmonary fibrosis

Using a new recipe for growing blood vessels from living lung tissue in the lab, a University of Virginia School of Engineering and Applied Science research team has developed an analytical tool that could lead to a cure for idiopathic pulmonary fibrosis, or IPF, a lung-destroying disease.

3 Oct 2023

Newly identified stem cell variants drive inflammation in cystic fibrosis patients

Two nationally recognized experts in cloning and stem cell science from the University of Houston, Wa Xian and Frank McKeon, are reporting that five lung stem cell variants dominate the lungs of patients with advanced cystic fibrosis (CF), and that these variants drive key aspects of CF pathology including inflammation, fibrosis and mucin secretion.

28 Sep 2023